These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 1253124)

  • 21. High incidence of adriamycin cardiotoxicity in children even at low cumulative doses: role of radionuclide cardiac angiography.
    Agarwala S; Kumar R; Bhatnagar V; Bajpai M; Gupta DK; Mitra DK
    J Pediatr Surg; 2000 Dec; 35(12):1786-9. PubMed ID: 11101737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anthracycline cardiotoxicity and acute myelogenous leukaemia.
    Al-Ismail SA; Parry DH; Whittaker JA
    Br Med J; 1977 Mar; 1(6064):815. PubMed ID: 265741
    [No Abstract]   [Full Text] [Related]  

  • 23. Risk factors for development of daunorubicin cardiotoxicity.
    Von Hoff DD; Layard M
    Cancer Treat Rep; 1981; 65 Suppl 4():19-23. PubMed ID: 7049377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anthracycline cardiomyopathy in children: report of two cases.
    Mosijczuk AD; Ruymann FB; Mease AD; Bernier RD
    Cancer; 1979 Nov; 44(5):1582-7. PubMed ID: 291472
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Doxorubicin-induced congestive heart failure in adults.
    Haq MM; Legha SS; Choksi J; Hortobagyi GN; Benjamin RS; Ewer M; Ali M
    Cancer; 1985 Sep; 56(6):1361-5. PubMed ID: 4027874
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy.
    Pein F; Sakiroglu O; Dahan M; Lebidois J; Merlet P; Shamsaldin A; Villain E; de Vathaire F; Sidi D; Hartmann O
    Br J Cancer; 2004 Jul; 91(1):37-44. PubMed ID: 15162142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiotoxicity of anthracycline antineoplastic drugs--Clinicopathological and experimental studies.
    Suzuki T; Kanda H; Kawai Y; Tominaga K; Murata K
    Jpn Circ J; 1979 Nov; 43(11):1000-8. PubMed ID: 522231
    [No Abstract]   [Full Text] [Related]  

  • 28. Toxicologic screening of daunorubicin (NSC-82151), adriamycin (NSC-123127), and their derivatives in rats.
    Zbinden G; Brändle E
    Cancer Chemother Rep; 1975; 59(4):707-15. PubMed ID: 1175165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Is the use of adriamycin (doxorubicin) limited by its cardiotoxicity?].
    Reinhardt D; Hofmann V; Martz G
    Schweiz Med Wochenschr; 1985 Apr; 115(16):557-61. PubMed ID: 4001904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Long-term study of anthracycline-induced cardiomyopathy in children and adolescents].
    Koch H; Schmitz L; Brockmeier K; Hartmann R; Bein G; Henze G
    Klin Padiatr; 1991; 203(4):262-7. PubMed ID: 1942932
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adriamycin (doxorubicin) cardiotoxicity: a review.
    Chlebowski RT
    West J Med; 1979 Nov; 131(5):364-8. PubMed ID: 394479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiotoxicity in children treated with anthracyclines: the role of M-mode echocardiography.
    Galli MA; Conter V; Zanetto F; Jankovic M; Ferrari L; Baio G; Masera G
    Haematologica; 1987; 72(4):347-50. PubMed ID: 3117636
    [No Abstract]   [Full Text] [Related]  

  • 33. [Daunomycin-and adriamycin-induced cardiomyopathy--relationship between dosage of drugs and histopathological findings (author's transl)].
    Yamaguchi H; Toyota S; Takahara O; Ichimaru M
    Rinsho Ketsueki; 1978 Aug; 19(8):1041-50. PubMed ID: 713049
    [No Abstract]   [Full Text] [Related]  

  • 34. Doxorubicin cardiotoxicity: possible role of digoxin in its prevention.
    Guthrie D; Gibson AL
    Br Med J; 1977 Dec; 2(6100):1447-9. PubMed ID: 589261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systolic time intervals in monitoring for anthracycline cardiomyopathy in pediatric patients.
    Hutchinson RJ; Bailey C; Wood D; Donaldson MH
    Cancer Treat Rep; 1978 Jun; 62(6):907-10. PubMed ID: 667866
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adriamycin cardiotoxicity in man.
    Rinehart JJ; Lewis RP; Balcerzak SP
    Ann Intern Med; 1974 Oct; 81(4):475-8. PubMed ID: 4277990
    [No Abstract]   [Full Text] [Related]  

  • 37. Comparison of daunorubicin (NSC-83142) with adriamycin (NSC-123127) in the treatment of late-stage childhood solid tumors.
    Evans AE; Baehner RL; Chard RL; Leikin SL; Pang EM; Pierce M
    Cancer Chemother Rep; 1974; 58(5 Pt 1):671-6. PubMed ID: 4371948
    [No Abstract]   [Full Text] [Related]  

  • 38. Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value.
    Skubitz KM; Blaes AH; Konety SH; Francis GS
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):787-798. PubMed ID: 28856562
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiotoxicity and comparative pharmacokinetics of six anthracyclines in the rabbit.
    Jaenke RS; Deprez-DeCampeneere D; Trouet A
    Cancer Res; 1980 Oct; 40(10):3530-6. PubMed ID: 6934026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin-D and mithramycin.
    Kushner JP; Hansen VL; Hammar SP
    Cancer; 1975 Nov; 36(5):1577-84. PubMed ID: 172214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.